RESUMO
BACKGROUND: Limited data exist regarding treatment response prediction to oral disease-modifying therapies (DMTs) in multiple sclerosis (MS). OBJECTIVES: We assessed the capacity of available scoring systems to anticipate disease activity parameters in naïve relapsing-remitting MS (RRMS) patients initiating daily oral DMTs, hypothesizing that they exhibit different predictive potentials. METHODS: We conducted a retrospective study and applied the Rio Score (RS), modified Rio Score (mRS), and MAGNIMS Score 12 months after DMT initiation. At 36 months, we examined their ability to predict evidence of disease activity (EDA) components and treatment failure by logistic regression analysis. RESULTS: Notably, 218 patients (62.4% females) initiating dimethyl fumarate, teriflunomide, and fingolimod were included. At 36 months, the RS high-risk group predicted evidence of clinical activity (odds ratio (OR) 10 [2.7-36.9]) and treatment failure (OR 10.6 [3.4-32.5]) but did not predict radiological activity (OR 1.9 [0.7-5]). The mRS non-responders group did not predict EDA and treatment failure. RS, mRS, and MAGNIMS 0 categories showed significantly lower EDA and treatment failure than the remainder. CONCLUSION: Scoring systems present different predictive abilities for disease activity parameters at 36 months in MS patients initiating daily oral therapies, warranting further adjustments (i.e. introduction of fluid biomarkers) to depict disease activity status fully.
Assuntos
Esclerose Múltipla Recidivante-Remitente , Falha de Tratamento , Humanos , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Feminino , Adulto , Masculino , Estudos Retrospectivos , Administração Oral , Pessoa de Meia-Idade , Cloridrato de Fingolimode/administração & dosagem , Fumarato de Dimetilo/administração & dosagem , Crotonatos/administração & dosagem , Hidroxibutiratos , Toluidinas/administração & dosagem , Imunossupressores/administração & dosagem , Nitrilas/administração & dosagem , Prognóstico , Fatores Imunológicos/administração & dosagemRESUMO
BACKGROUND: Multiple Sclerosis (MS) a central nervous system autoimmune disorder, mainly affecting young adults and more prevalent among women, can lead to sexual dysfunction (SD) among both males and females with MS. Female sexual dysfunction can be defined as dyspareunia, a lack of sexual desire, disorders in the arousal and orgasm phases, and sexual pain disorders. The purpose of this study is to investigate the changes in sexual function among females with MS whose treatment was switched from first-line injectable medications to other agents after a six-month duration. And assess the changes in all three domains of SD. METHODS: In this longitudinal study females diagnosed with MS, aged between 18 and 50 years old, and were candidates for switching their treatment from interferon beta-1a (intra-muscular and subcutaneous), and Glatiramer Acetate (GA), to Fingolimod, Dimethyl Fumarate (DMF), or Natalizumab (NTZ) due to patients' convenience and tolerability and adverse events were included. "Multiple Sclerosis Intimacy and Sexuality Questionnaire-19" was used to evaluate the SD changes before and six months after the new treatment initiation. Statistical analysis was conducted using SPSS V.24 software. Histograms and the Shapiro-Wilk test were used to assess the normality of the variables; due to the non-normal distribution of quantitative variables (except for age), the Wilcoxon signed-rank test was used to compare the scores, before and six months after the medication change. The level of significance was considered less than 0.05. RESULTS: Out of 107 female participants (average age: 35.09 ± 5.61), The mean of overall MSISQ-19 scores, before and six months after the medication change were not significant (p-value = 0.091). However, considering the subdomains, the medication changes only affected the tertiary subdomain of MSISQ-19 (p-value = 0.017). Still, the scores of other subdomains did not change significantly (p-value = 0.761 for primary SD and 0.479 for secondary SD). Also, there wasn't any significant difference between EDSS before and after the medication change (p-value = 0.461). CONCLUSIONS: To our knowledge, this was the first study, assessing the effect of MS medication change on the improvement of SD among patients. According to the results of the presented cross-sectional study, we found that during a six-month period, the tertiary subdomain of MSISQ-19 symptoms improved significantly, while the changes in other SD domains were not significant.
Assuntos
Acetato de Glatiramer , Esclerose Múltipla , Disfunções Sexuais Fisiológicas , Humanos , Feminino , Adulto , Esclerose Múltipla/tratamento farmacológico , Esclerose Múltipla/complicações , Pessoa de Meia-Idade , Disfunções Sexuais Fisiológicas/etiologia , Disfunções Sexuais Fisiológicas/tratamento farmacológico , Estudos Longitudinais , Acetato de Glatiramer/administração & dosagem , Acetato de Glatiramer/uso terapêutico , Adulto Jovem , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/uso terapêutico , Fumarato de Dimetilo/administração & dosagem , Fumarato de Dimetilo/uso terapêutico , Adolescente , Imunossupressores/uso terapêutico , Imunossupressores/administração & dosagem , Interferon beta-1a/administração & dosagem , Interferon beta-1a/uso terapêutico , Substituição de Medicamentos/métodos , Cloridrato de Fingolimode/uso terapêutico , Cloridrato de Fingolimode/administração & dosagem , Natalizumab/administração & dosagem , Natalizumab/uso terapêuticoRESUMO
Background: The primary treatment for acute relapses in multiple sclerosis (MS) is the intravenous administration of high-dose methylprednisolone (IVMP). However, the mechanisms through which corticosteroid treatment impacts acute neuroinflammation in people with MS (pwMS) remain not fully understood. In particular, the changes induced by glucocorticoids (GCs) on cells of the innate immune system and the differences between patients with distinct immunotherapies have received little attention to date. Methods: We conducted immunophenotyping using flow cytometry on peripheral blood mononuclear cells of pwMS who received IVMP treatment during a relapse. We compared the impact of an IVMP treatment on a broad variety of immune cell subsets within three groups: twelve patients who were treatment-naïve to disease modifying therapies (wDMT) to ten patients on platform therapies (PT) and eighteen patients on fingolimod therapy (FTY). Results: We observed pronounced interindividual short- and intermediate-term effects of IVMP on distinct immune cells subsets. In addition to the well-documented decrease in T-helper cells (Th cells), we detected significant alterations after the first IVMP infusion within the innate immune response among neutrophil, eosinophil and basophil granulocytes, monocytes and plasmacytoid dendritic cells (pDCs). When comparing patients wDMT to the PT and FTY cohorts, we found that IVMP had a similar impact on innate immune cells across all treatment groups. However, we did not observe a significant further decline in T lymphocyte counts during IVMP in patients with pre-existing lymphopenia under FTY treatment. Although T cell apoptosis is considered the main mechanism of action of GCs, patients with FTY still reported symptom improvement following IVMP treatment. Conclusion: In addition to T cell suppression, our data suggests that further immunoregulatory mechanisms of GC, particularly on cells of the innate immune response, are of greater significance than previously understood. Due to the regulation of the adaptive immune cells by DMTs, the impact of GC on these cells varies depending on the underlying DMT. Additional studies involving larger cohorts and cerebrospinal fluid samples are necessary to gain a deeper understanding of the immune response to GC in pwMS with different DMTs during relapse to define and explain differences in clinical response profiles.
Assuntos
Esclerose Múltipla , Humanos , Feminino , Masculino , Adulto , Pessoa de Meia-Idade , Esclerose Múltipla/tratamento farmacológico , Esclerose Múltipla/imunologia , Cloridrato de Fingolimode/uso terapêutico , Cloridrato de Fingolimode/administração & dosagem , Imunidade Inata/efeitos dos fármacos , Metilprednisolona/uso terapêutico , Metilprednisolona/administração & dosagem , Imunofenotipagem , Leucócitos Mononucleares/imunologia , Corticosteroides/uso terapêutico , Corticosteroides/administração & dosagem , Imunossupressores/uso terapêutico , Glucocorticoides/uso terapêutico , Glucocorticoides/administração & dosagemRESUMO
BACKGROUND: This study investigates the gap in understanding the dynamics of recurring disease activity (RDA) in RRMS patients after fingolimod (FGL) treatment discontinuation. The aim is to investigate RDA in RRMS patients after stopping FGL, aiming to improve management and comprehension of disease progression post-treatment. METHODS: In this multicenter, retrospective study, data from 172 of 944 RRMS patients aged 18-55, across nine centers in Turkey, who discontinued FGL treatment, were analyzed. The collected data included EDSS scores, annualized relapse rates (ARR), lymphocyte counts, and MRI findings, with follow-up assessments conducted at 6 months, 1 year, and up to 2 years. RESULTS: RDA was observed in 31.9 % of patients, with incidences of rebound and reactivation at 20.3 % and 11.6 %, respectively. Factors like younger age, longer treatment duration, lower lymphocyte counts, and higher lesion burden increased RDA risk. Notably, 52.9 % of pregnant patients experienced RDA (16.4 % of the overall RDA group), with rebound occurring in six and reactivation in three. Patients with RDA had longer medication-free intervals and increased ARR. Discontinuation reasons varied, with disease progression linked to a lower RDA risk. CONCLUSION: Findings highlight the necessity for personalized management and vigilant monitoring after FGL discontinuation in RRMS patients, offering critical insights into RDA risk factors, and the complex interplay between treatment cessation, pregnancy, and disease progression.
Assuntos
Progressão da Doença , Cloridrato de Fingolimode , Imunossupressores , Esclerose Múltipla Recidivante-Remitente , Recidiva , Humanos , Adulto , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Esclerose Múltipla Recidivante-Remitente/diagnóstico por imagem , Esclerose Múltipla Recidivante-Remitente/fisiopatologia , Feminino , Masculino , Estudos Retrospectivos , Adulto Jovem , Pessoa de Meia-Idade , Adolescente , Cloridrato de Fingolimode/administração & dosagem , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Turquia , Gravidez , Seguimentos , Imageamento por Ressonância MagnéticaRESUMO
BACKGROUND: Real-world effectiveness can vary across oral disease-modifying agents (DMAs) and their adherence trajectories in patients with multiple sclerosis (MS). However, previous studies have not considered longitudinal adherence patterns while evaluating oral DMAs. OBJECTIVES: This study aimed to evaluate the association of oral DMAs and their adherence trajectories with annualized relapse rate (ARR) in patients with MS. METHODS: This retrospective observational cohort study based on the 2015-2019 MarketScan Commercial Claims and Encounters Database involved continuous enrolled adults (18-64 years) with ≥1 MS diagnosis (ICD-9/10-CM:340/G35) and ≥ 1 oral DMA prescription. Patients were grouped into incident fingolimod (FIN), teriflunomide (TER), and dimethyl fumarate (DMF) users based on the index DMA with a one-year washout period. Annual DMA adherence trajectories based on the monthly Proportion of Days Covered (PDC) one year after treatment initiation were identified using Group-Based Trajectory Modeling (GBTM). The validated claims-based ARR was evaluated during the one-year follow-up period using generalized boosted model-based inverse probability treatment weights with negative binomial regression model. RESULTS: The study cohort consisted of 994 MS patients who initiated with FIN (23.0%), TER (22.3%), and DMF (54.7%) during the study period. GBTM grouped eligible patients into three adherence trajectories: complete adherers (59.2%), slow decliners (23.8%), and rapid decliners (17.0%). The proportion of complete adherers varied across the oral DMAs (FIN: 67.1%, TER: 55.4%, and DMF: 57.4%). The negative binomial regression modeling revealed that, while there was no difference in ARR across the three DMAs, rapid decliners (adjusted incidence rate ratio[aIRR]: 1.6, 95% CI: 1.1-2.4) had a higher rate of relapses compared to completely adherent patients. The type of oral DMAs did not moderate the relationship between ARR and the adherence trajectory groups. CONCLUSIONS: Adherence trajectories classified as rapid decliners were associated with a higher ARR than complete adherers after adjusting for their type of oral DMAs. Longitudinal medication adherence patterns are critical in reducing relapse rates in MS.
Assuntos
Crotonatos , Fumarato de Dimetilo , Cloridrato de Fingolimode , Hidroxibutiratos , Adesão à Medicação , Nitrilas , Recidiva , Toluidinas , Humanos , Adulto , Feminino , Masculino , Adesão à Medicação/estatística & dados numéricos , Pessoa de Meia-Idade , Crotonatos/administração & dosagem , Crotonatos/uso terapêutico , Estudos Retrospectivos , Toluidinas/administração & dosagem , Toluidinas/uso terapêutico , Adulto Jovem , Fumarato de Dimetilo/administração & dosagem , Fumarato de Dimetilo/uso terapêutico , Cloridrato de Fingolimode/uso terapêutico , Cloridrato de Fingolimode/administração & dosagem , Adolescente , Esclerose Múltipla/tratamento farmacológico , Administração Oral , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Fatores Imunológicos/administração & dosagemRESUMO
This study reports on the design and synthesis of hypoxia responsive nanoparticles (HRNPs) composed of methoxy polyethylene glycol-4,4 dicarboxylic azolinker-chitosan (mPEG-Azo-chitosan) as ideal drug delivery platform for Fingolimod (FTY720, F) delivery to achieve selective and highly enhanced TNBC therapy in vivo. Herein, HRNPs with an average size of 49.86 nm and a zeta potential of +3.22 mV were synthetized, which after PEG shedding can shift into a more positively-charged NPs (+30.3 mV), possessing self-activation ability under hypoxia situation in vitro, 2D and 3D culture. Treatment with lower doses of HRNPs@F significantly reduced MDA-MB-231 microtumor size to 15 %, induced apoptosis by 88 % within 72 h and reduced highly-proliferative 4 T1 tumor weight by 87.66 % vs. â¼30 % for Fingolimod compared to the untreated controls. To the best of our knowledge, this is the first record for development of hypoxia-responsive chitosan-based NPs with desirable physicochemical properties, and selective self-activation potential to generate highly-charged nanosized tumor-penetrating chitosan NPs. This formulation is capable of localized delivery of Fingolimod to the tumor core, minimizing its side effects while boosting its anti-tumor potential for eradication of TNBC solid tumors.
Assuntos
Quitosana , Cloridrato de Fingolimode , Nanopartículas , Quitosana/química , Quitosana/análogos & derivados , Nanopartículas/química , Humanos , Animais , Linhagem Celular Tumoral , Cloridrato de Fingolimode/farmacologia , Cloridrato de Fingolimode/química , Cloridrato de Fingolimode/administração & dosagem , Camundongos , Feminino , Portadores de Fármacos/química , Apoptose/efeitos dos fármacos , Polietilenoglicóis/química , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Neoplasias de Mama Triplo Negativas/patologiaRESUMO
Although treatments for myocardial infarction have advanced significantly, the global mortality due to ischemia and subsequent reperfusion injury remains high. Here, a platelet (PLT) membrane nanocarrier (PL720) that encapsulates L-arginine and FTY720 to facilitate the cascade-targeted delivery of these substances to the myocardial injury site and enable the controlled release of L-arginine and FTY720 is developed. Such an innovative approach shows enhanced cardioprotection through multiple target strategies involved in ischemia-reperfusion injury and late reperfusion inflammation. During the ischemia-reperfusion phase, PL720 targets and accumulates in damaged coronary arteries. PL720 rapidly releases L-arginine, stimulating endothelial cells to produce NO, thereby dilating blood vessels and promoting blood flow recovery, while FTY720's sustained release exerts anti-apoptotic effects. During the late reperfusion inflammatory phase, PL720 is captured by circulating inflammatory monocytes and transported into a deeper ischemic myocardial lesion. PL720 promotes macrophage polarization and accelerates the inflammatory repair. Furthermore, the issue of bradycardia associated with the clinical use of FTY720 is innovatively relieved. Therefore, PL720 is a vascular injury and inflammation dual targeting strategy, exhibiting significant potential for multi-targeted therapy and clinical translation for cardiac injury.
Assuntos
Plaquetas , Modelos Animais de Doenças , Sistemas de Liberação de Medicamentos , Traumatismo por Reperfusão Miocárdica , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Animais , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Sistemas de Liberação de Medicamentos/métodos , Remodelação Ventricular/efeitos dos fármacos , Cloridrato de Fingolimode/administração & dosagem , Cloridrato de Fingolimode/farmacologia , Camundongos , Masculino , Ratos , Humanos , Nanopartículas/administração & dosagemRESUMO
BACKGROUND: Observational studies looking at clinical a++nd MRI outcomes of treatments in pediatric MS, could assess current treatment algorithms, and provide insights for designing future clinical trials. OBJECTIVE: To describe baseline characteristics and clinical and MRI outcomes in MS patients initiating ocrelizumab and fingolimod under 18 years of age. METHODS: MS patients seen at 12 centers of US Network of Pediatric MS were included in this study if they had clinical and MRI follow-up and started treatment with either ocrelizumab or fingolimod prior to the age of 18. RESULTS: Eighty-seven patients initiating fingolimod and 52 initiating ocrelizumab met the inclusion criteria. Before starting fingolimod, mean annualized relapse rate was 0.43 (95 % CI: 0.29 - 0.65) and 78 % developed new T2 lesions while during treatment it was 0.12 (95 % CI: 0.08 - 1.9) and 47 % developed new T2 lesions. In the ocrelizumab group, the mean annualized relapse rate prior to initiation of treatment was 0.64 (95 % CI: 0.38-1.09) and a total of 83 % of patients developed new T2 lesions while during treatment it was 0.09 (95 % CI: 0.04-0.21) and none developed new T2 lesions. CONCLUSION: This study highlights the importance of evaluating current treatment methods and provides insights about the agents in the ongoing phase III trial comparing fingolimod and ocrelizumab.
Assuntos
Anticorpos Monoclonais Humanizados , Cloridrato de Fingolimode , Imageamento por Ressonância Magnética , Humanos , Cloridrato de Fingolimode/efeitos adversos , Cloridrato de Fingolimode/uso terapêutico , Cloridrato de Fingolimode/administração & dosagem , Feminino , Masculino , Adolescente , Anticorpos Monoclonais Humanizados/efeitos adversos , Anticorpos Monoclonais Humanizados/administração & dosagem , Criança , Fatores Imunológicos/efeitos adversos , Fatores Imunológicos/administração & dosagem , Imunossupressores/efeitos adversos , Imunossupressores/administração & dosagem , Esclerose Múltipla/tratamento farmacológico , Esclerose Múltipla/diagnóstico por imagem , Resultado do Tratamento , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Encéfalo/patologiaRESUMO
Purpose: Spinal cord injury (SCI) is an incurable and disabling event that is accompanied by complex inflammation-related pathological processes, such as the production of excessive reactive oxygen species (ROS) by infiltrating inflammatory immune cells and their release into the extracellular microenvironment, resulting in extensive apoptosis of endogenous neural stem cells. In this study, we noticed the neuroregeneration-promoting effect as well as the ability of the innovative treatment method of FTY720-CDs@GelMA paired with NSCs to increase motor function recovery in a rat spinal cord injury model. Methods: Carbon dots (CDs) and fingolimod (FTY720) were added to a hydrogel created by chemical cross-linking GelMA (FTY720-CDs@GelMA). The basic properties of FTY720-CDs@GelMA hydrogels were investigated using TEM, SEM, XPS, and FTIR. The swelling and degradation rates of FTY720-CDs@GelMA hydrogels were measured, and each group's ability to scavenge reactive oxygen species was investigated. The in vitro biocompatibility of FTY720-CDs@GelMA hydrogels was assessed using neural stem cells. The regeneration of the spinal cord and recovery of motor function in rats were studied following co-treatment of spinal cord injury using FTY720-CDs@GelMA hydrogel in combination with NSCs, utilising rats with spinal cord injuries as a model. Histological and immunofluorescence labelling were used to determine the regeneration of axons and neurons. The recovery of motor function in rats was assessed using the BBB score. Results: The hydrogel boosted neurogenesis and axonal regeneration by eliminating excess ROS and restoring the regenerative environment. The hydrogel efficiently contained brain stem cells and demonstrated strong neuroprotective effects in vivo by lowering endogenous ROS generation and mitigating ROS-mediated oxidative stress. In a follow-up investigation, we discovered that FTY720-CDs@GelMA hydrogel could dramatically boost NSC proliferation while also promoting neuronal regeneration and synaptic formation, hence lowering cavity area. Conclusion: Our findings suggest that the innovative treatment of FTY720-CDs@GelMA paired with NSCs can effectively improve functional recovery in SCI patients, making it a promising therapeutic alternative for SCI.
Assuntos
Cloridrato de Fingolimode , Hidrogéis , Células-Tronco Neurais , Ratos Sprague-Dawley , Traumatismos da Medula Espinal , Animais , Traumatismos da Medula Espinal/tratamento farmacológico , Traumatismos da Medula Espinal/terapia , Cloridrato de Fingolimode/farmacologia , Cloridrato de Fingolimode/química , Cloridrato de Fingolimode/administração & dosagem , Células-Tronco Neurais/efeitos dos fármacos , Hidrogéis/química , Hidrogéis/farmacologia , Hidrogéis/administração & dosagem , Ratos , Recuperação de Função Fisiológica/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Pontos Quânticos/química , Modelos Animais de Doenças , Feminino , Medula Espinal/efeitos dos fármacosRESUMO
BACKGROUND: The long-term effect of high efficacy disease modifying therapy (DMT) on neurodegeneration in people with multiple sclerosis (pwMS) is largely unknown. The aim of this study was to evaluate the long-term effect of natalizumab (NTZ) or fingolimod (FTY) therapy on the evolution of brain atrophy compared to moderate efficacy DMT in a real-world clinical setting. METHODS: A total of 438 pwMS with 2,439 MRI exams during treatment were analyzed: 252 pwMS treated with moderate efficacy DMT, 130 with NTZ and 56 with FTY. Evolution of brain atrophy was analyzed over an average follow-up of 6.6 years after treatment initiation. Brain segmentation was performed on clinical 3D-FLAIRs using SynthSeg and regional brain volume changes over time were compared between the treatment groups. RESULTS: Total brain, white matter and deep gray matter atrophy rates did not differ between moderate efficacy DMTs, NTZ and FTY. Annualized ventricle growth rates were lower in pwMS treated with NTZ (1.1 %/year) compared with moderate efficacy DMT (2.4 %/year, p < 0.001) and similar to FTY (2.0 %/year, p = 0.051). Cortical atrophy rates were lower in NTZ (-0.08 %/year) compared with moderate efficacy DMT (-0.16 %/year, p = 0.048). CONCLUSION: In a real-world clinical setting, pwMS treated with NTZ had slower ventricular expansion and cortical atrophy compared to those treated with moderate efficacy DMT.
Assuntos
Atrofia , Encéfalo , Cloridrato de Fingolimode , Fatores Imunológicos , Imageamento por Ressonância Magnética , Esclerose Múltipla , Natalizumab , Humanos , Cloridrato de Fingolimode/farmacologia , Cloridrato de Fingolimode/uso terapêutico , Cloridrato de Fingolimode/administração & dosagem , Natalizumab/farmacologia , Natalizumab/administração & dosagem , Natalizumab/uso terapêutico , Feminino , Masculino , Adulto , Pessoa de Meia-Idade , Esclerose Múltipla/tratamento farmacológico , Esclerose Múltipla/patologia , Esclerose Múltipla/diagnóstico por imagem , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Fatores Imunológicos/farmacologia , Fatores Imunológicos/administração & dosagem , Fármacos Neuroprotetores/farmacologia , Fármacos Neuroprotetores/administração & dosagem , SeguimentosRESUMO
Conclusion Bioequivalence Results: A total of 40 subjects were planned and enrolled in the study. Thirty-nine (39) subjects completed the clinical phase of the study and data of thirty-nine (39) subjects were considered for pharmacokinetic and statistical analysis. The 90 % CI's of Ln-transformed parameters for Fingolimod are summarized below: Safety results: Two (02) AEs were reported during the clinical phase of the study which were unexpected and not related to study drug, mild in severity and were considered for lost to follow up. No serious AEs (SAEs) were observed during the clinical phase. Conclusion: Based on the statistical analysis of Fingolimod on 39 subjects, it is concluded that the Test Product (T): Fibroneurina manufactured by Laboratorios Bagó, Argentina shows bioequivalence with the Reference Product Fingolimod 0.5 mg hard capsules Manufactured by Novartis Pharma GmbH, Germany. Date of the report: 04 February 2017
Assuntos
Humanos , Cápsulas/farmacocinética , Equivalência Terapêutica , Análise Prévia de Produtos , Cloridrato de Fingolimode/administração & dosagemRESUMO
ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.
RESUMO Objetivo Avaliar a segurança na mudança entre natalizumabe e fingolimode sem período de washout. Métodos Dados prospectivos de 25 pacientes positivos para vírus JC que tiveram sua medicação modificada foram coletados e analisados. Resultados Após uma mediana de nove meses da troca de medicação, não havia aspectos de segurança a relatar. Os pacientes estavam com bom controle da doença e não foram relatados eventos adversos. Conclusão Washout pode não ser necessário na prática diária para a mudança entre natalizumabe e fingolimode. No entanto, expertise no manejo de esclerose múltipla é essencial para esta troca entre medicações.
Assuntos
Humanos , Masculino , Feminino , Adulto , Substituição de Medicamentos , Cloridrato de Fingolimode/administração & dosagem , Natalizumab/administração & dosagem , Imunossupressores/administração & dosagem , Esclerose Múltipla/tratamento farmacológico , Estudos Prospectivos , Leucoencefalopatia Multifocal Progressiva/complicações , Leucoencefalopatia Multifocal Progressiva/virologia , Resultado do Tratamento , Vírus JC/efeitos dos fármacos , Vírus JC/imunologia , Carga Viral , Cloridrato de Fingolimode/efeitos adversos , Natalizumab/efeitos adversos , Imunossupressores/efeitos adversos , Esclerose Múltipla/complicaçõesRESUMO
CONTEXTO: A Esclerose Múltipla (EM) é uma doença autoimune, desmielinizante, crônica do sistema nervoso central, comum em adultos jovens, predominante entre mulheres, com evolução progressiva e imprevisível. A incidência mundial é de 2,5 casos novos a cada 100.000 pessoas por ano e no Brasil sua taxa de prevalência média é de aproximadamente 15 casos/100.000 habitantes, variando entre as regiões e sendo mais prevalente nas regiões sul e sudeste. Atualmente, segundo PCDT vigente (Portaria SAS/MS nº 493, de 23 de setembro de 2010), acetato de glatirâmer e betainterferona (1A ou 1B) são os fármacos de primeira escolha para o tratamento de Esclerose Múltipla Remitente Recorrente (EMRR). O uso de natalizumabe ocorre em casos refratários, tanto às betainterferonas quanto a glatirâmer. Atualmente, existem 11.650 pacientes recebendo betainterferonas, acetato de glatirâmer e natalizumabe para o tratamento de EM (DATASUS). TRATAMENTO: O tratamento é preconizado apenas para as formas EM-RR e EM-SP, pois não há evidência de benefício para as demais. O Protocolo Clínico e Diretrizes Terapêuticas da Esclerose Múltipla do Ministério da Saúde publicado em novembro de 2013 preconiza as betainterferonas e glatirâmer como primeira escolha e recomenda que o natalizumabe seja iniciado somente em casos refratários tanto a betainterferonas quanto a glatirâmer. A CONITEC já avaliou outras demandas por incorporação do fingolimode ao tratamento de esclerose múltipla no SUS, tendo emitido o relatório número 04, de julho de 2012, no qual não recomendou a incorporação desta tecnologia para a primeira linha de tratamento da esclerose múltipla. O relatório, à época, trouxe como um dos motivos para a não incorporação do medicamento os dados de segurança, que demandava a realização de estudos clínicos de fase IV ou de pós-comercialização a fim de avaliar a segurança do medicamento, especialmente os efeitos adversos cardiovasculares, para que então se reavaliasse a relação risco e benefício da tecnologia. A TECNOLOGIA: Fingolimode é indicado como terapia modificadora de doença para tratamento de pacientes adultos com esclerose múltipla remitente recorrente para reduzir a freqüência de reincidências e retardar a progressão da incapacidade7 (CID G35.0, ou seja, esclerose múltipla). EVIDÊNCIAS CIENTÍFICAS: os demandantes apresentaram em seus pareceres técnico-científicos as buscas realizadas por evidências científicas. Nos três casos, a pergunta de pesquisa foi adequada, considerando os comparadores disponíveis no SUS. Nas três propostas encaminhadas, os demandantes selecionaram o estudo que comparou o fingolimode ao betainterferona-1a (TRANSFORMS) e mais dois artigos que derivaram deste estudo principal, um de extensão do estudo e outro de análise de subgrupo. Os três estudos são de nível de evidência 1B, segundo maior nível de evidência. Os resultados apontam para eficácia superior do fingolimode em relação ao betainterferona-1a, porém ainda há incertezas sobre os resultados de segurança, especialmente para o uso em primeira linha. DELIBERAÇÃO FINAL: Com discussão posterior à Consulta Pública, tendo como base a ausência de dados novos que superassem a incerteza quanto ao balanço de riscos e benefícios do uso do fingolimode em primeira e segunda linha, devido, sobretudo, aos potenciais eventos cardiovasculares relacionados à primeira dose do fingolimode, os membros do plenário, na reunião realizada nos dias 7 e 8/5/2014, deliberaram, por unanimidade, por não recomendar a incorporação do fingolimode para a primeira e segunda linha do tratamento da esclerose múltipla. DECISÕES: PORTARIA Nº 24, de 27 de junho de 2014 - Torna pública a decisão de incorporar o fingolimode no Sistema Único de Saúde nos casos de: pacientes com esclerose múltipla remitente-recorrente; com surtos incapacitantes após falha ao uso de betainterferona e de glatirâmer; com impossibilidade de uso de natalizumabe e sem contraindicação ao uso de fingolimode conforme Protocolo Clínico e Diretrizes Terapêuticas.
Assuntos
Humanos , Interferon beta/efeitos adversos , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Cloridrato de Fingolimode/administração & dosagem , Acetato de Glatiramer/efeitos adversos , Natalizumab , Sistema Único de Saúde , Brasil , Análise Custo-Benefício/economia , Falha de TratamentoRESUMO
La esclerosis múltiple (EM), es una enfermedad autoinmune, crónica, inflamatoria, desmielinizante del sistema nervioso central (SNC) que se presenta en individuos genéticamente susceptibles y que involucra a factores inmunológicos como anticuerpos, complementos, mediadores de la respuesta innata. Es considerada dentro de las enfermedades desmielinizantes inflamatorias idiopáticas, y constituye una de las causas más frecuentes de discapacidad neurológica en adultos jóvenes. Como resultado de la utilización de fingolimod en pacientes con esclerosis múltiple se observó mejoras la tasa anual de recaídas. Se recomienda cubrir.(AU)